Rahman I, Bel A, Mulier B, Lawson MF, Harrison DJ, MacNee W, and Smith CA (1996)
Thus, it is imperative to promote weight loss to reduce severe complications ( 2 and a BMI of 27 kg/m 2 with weight-related comorbidities, stimulate satiety, reduce hunger, and/or reduce fat absorption or catabolism ( Figure 1 2 Physiological mechanism of the dual GIP/GLP-1 receptor agonist on weight loss: Evidence from preclinical studies GLP-1 is a peptide that is synthesized by L cells of the intestine, and once GLP-1 is released, it binds to its receptor expressed in -cells, cells, the kidneys, the lungs, gastric mucosa, the heart, the brain, and immune cells ( via GABA-dependent signaling ( Some studies have demonstrated that the co-administration of GLP-1 and GIP acts synergistically on receptors that activate -cells ( in vitro and in vivo studies
Clinical data suggests dual therapy may offer additive glucose-lowering effects in specific type 2 diabetes cases, though individual response varies significantly
Our study showed that L-carnitine reverses the TNF--induced muscle cell atrophy caused by regulation of the Akt/P70S6K/FOXO3a pathways, and by inhibiting muscle-specific ubiquitin ligases
Ueda P, Wintzell V, Melbye M, Eliasson B, Soderling J, Gudbjornsdottir S, et al
